Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

about

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety.

P2860

Q36535465-2ACDB622-404E-4006-971C-36045DAA7E13 Q46529985-D95D66EC-EAC0-4DEF-A36B-49A05F7ED102

P2860

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38514440

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Axitinib: from preclinical dev ...... tives in renal cell carcinoma.

@en

type

Item

label

Axitinib: from preclinical dev ...... tives in renal cell carcinoma.

@en

prefLabel

Axitinib: from preclinical dev ...... tives in renal cell carcinoma.

@en

P1476

Axitinib: from preclinical dev ...... tives in renal cell carcinoma.

@en

P2093

Kais Zakharia

http://www.w3.org/2001/XMLSchema#string

Yousef Zakharia

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Sorafenib in advanced clear-cell renal-cell carcinoma

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

P304

925-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2015.1045411

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Rixe

P577

2015-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26039031

http://www.w3.org/2001/XMLSchema#string

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

about

P2860

P2860

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698